Your session is about to expire
← Back to Search
ADX-629 for Sjogren-Larsson Syndrome
Study Summary
This trial will study whether a drug is safe and effective in people with a rare disease called Sjögren-Larsson syndrome. The disease is caused by mutations in a gene and leads to the build-up of harmful fats in the body. The drug, ADX-629, is an experimental aldehyde trapping agent that is expected to eliminate these harmful fats. The primary objective of the trial is to determine whether ADX-629 is safe and tolerable for use in SLS subjects. The secondary objective is to determine the efficacy of ADX-629 in reversing the biochemical abnormalities in SLS.
Timeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You had cancer within the last 5 years, except for certain types of skin or cervical cancer that have been treated with no sign of coming back.You have a history of serious liver or digestive system problems that could affect how the drug works in your body.You have kidney problems or your kidney function is not normal.You have been diagnosed with SLS and have specific genetic mutations in the ALDH3A2 gene.You have a history of serious heart problems or abnormal heart rhythms, or your electrocardiogram shows certain irregularities.You are currently taking medication that lowers your immune system and cannot stop taking it for at least 2 weeks during the study.You have a skin condition called ichthyosis and symptoms of muscle stiffness or spasms.
- Group 1: ADX-629 treatment
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Is it possible to partake in this clinical experiment?
"This clinical trial is hoping to enroll 10 people aged between 18 and 50 that have been diagnosed with sjogren-larsson syndrome. To be eligible, potential participants must provide written informed consent before any study procedures are initiated, weigh at least 35 kgs, demonstrate active ichthyosis and neurological symptoms of spasticity, abstain from all topical creams 7 days prior to initial baseline evaluation or the 12 week centre visit (if applicable), pass a negative pregnancy test if female of childbearing potential and adhere to medically approved contraceptive methods during the study duration or document being surgically sterile/postmenopausal; additionally they need to"
How many participants are currently enrolled in this research experiment?
"Absolutely. According to clinicaltrials.gov, this medical trial began on the 2nd of January 2023 and was last updated on the 7th of November 2022. At present, only 10 participants are needed from a single site for enrollment."
Is the enrollment for this trial still open to new participants?
"Clinicaltrials.gov reveals that this medical trial is open for recruitment, beginning from the initial post date of January 2nd 2023 and updated as recently as November 7th 2022."
Does this research involve participants aged more than twenty?
"This research is targeting individuals aged 18 and under 50 who are willing to participate."
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger